EP1077958A1 - Oxazole-aryl-carboxylic acids useful in the treatment of insulin resistance and hyperglycemia - Google Patents

Oxazole-aryl-carboxylic acids useful in the treatment of insulin resistance and hyperglycemia

Info

Publication number
EP1077958A1
EP1077958A1 EP99924163A EP99924163A EP1077958A1 EP 1077958 A1 EP1077958 A1 EP 1077958A1 EP 99924163 A EP99924163 A EP 99924163A EP 99924163 A EP99924163 A EP 99924163A EP 1077958 A1 EP1077958 A1 EP 1077958A1
Authority
EP
European Patent Office
Prior art keywords
carbon atoms
alkyl
hydrogen
aryl
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99924163A
Other languages
German (de)
French (fr)
Inventor
Michael Sotirios Malamas
Original Assignee
American Home Products Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Home Products Corp filed Critical American Home Products Corp
Publication of EP1077958A1 publication Critical patent/EP1077958A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Definitions

  • Hyperinsulinemia can be present as a result of insulin resistance, such as is in obese and/or diabetic (NIDDM) subjects and/or glucose intolerant subjects, or in IDDM subjects, as a consequence of over injection of insulin compared with normal physiological release of the hormone by the endocrine pancreas.
  • NIDDM diabetic diabetic
  • IDDM glucose intolerant subjects
  • Atherosclerosis has been well established by numerous experimental, clinical and epidemiological studies (summarized by Stout, Metabolism 1985, 34, 1, and in more detail by Pyorala et al, Diabetes/Metabolism Reviews 1987, 3, 463). Statistically significant plasma insulin elevations at 1 and 2 hours after oral glucose load correlates with an increased risk of coronary heart disease.
  • the independent risk factors obesity and hypertension for atherosclerotic diseases are also associated with insulin resistance.
  • insulin resistance is located in peripheral tissues (principally muscle) and correlates directly with the severity of hypertension (DeFronzo and Ferrannini, Diabetes Care 1991, 14, 173).
  • insulin resistance generates hyperinsulinemia, which is recruited as a mechanism to limit further weight gain via thermogenesis, but insulin also increases renal sodium reabsorption and stimulates the sympathetic nervous system in kidneys, heart, and vasculature, creating hypertension.
  • insulin resistance is usually the result of a defect in the insulin receptor signaling system, at a site post binding of insulin to the receptor.
  • Accumulated scientific evidence demonstrating insulin resistance in the major tissues which respond to insulin strongly suggests that a defect in insulin signal transduction resides at an early step in this cascade, specifically at the insulin receptor kinase activity, which appears to be diminished (reviewed by Haring, Diabetalogia 1991, 34, 848).
  • PTPases Protein-tyrosine phosphatases play an important role in the regulation of phosphorylation of proteins.
  • the interaction of insulin with its receptor leads to phosphorylation of certain tyrosine molecules within the receptor protein, thus activating the receptor kinase.
  • PTPases dephosphorylate the activated insulin receptor, attenuating the tyrosine kinase activity.
  • PTPases can also modulate post-receptor signaling by catalyzing the dephosphorylation of cellular substrates of the insulin receptor kinase.
  • the enzymes that appear most likely to closely associate with the insulin receptor and therefore, most likely to regulate the insulin receptor kinase activity include PTP1B, LAR, PTP ⁇ and SH-PTP2 (B.
  • the compounds of this invention have been shown to inhibit PTPases derived from rat liver microsomes and human-derived recombinant PTPase- IB (hPTP-lB) in vitro. They are useful in the treatment of insulin resistance associated with obesity, glucose intolerance, diabetes mellitus, hypertension and ischemic diseases of the large and small blood vessels.
  • This invention provides a compound of formula I having the structure
  • R 1 is alkyl of 1-6 carbon atoms, cycloalkyl of 3-8 carbon atoms, thienyl, furyl, pyridyl,
  • R 2 is hydrogen, alkyl of 1-6 carbon atoms, or aryl of 6 to 10 carbon atoms;
  • R 3 and R 4 are independently halogen, hydrogen, alkyl of 1-12 carbon atoms , aryl of 6 to 10 carbon atoms; halogen, trifluoromethylof 1-6 carbon atoms, alkoxyaryl of
  • R 5 is hydrogen, alkyl of 1-6 carbon atoms, -CH(R 8 )R 9 , -C(CH 2 ) n CO 2 R 10 ,
  • R 6 is hydrogen, alkyl of 1-6 carbon atoms, halogen, alkyoxy of 1-6 carbon atoms, trifluoroalkyl of 1-6 carbon atoms or trifluoroalkoxy of 1-6 carbon atoms;
  • R 7 is hydrogen or alkyl of 1 to 6 carbon atoms
  • R 8 is hydrogen, alkyl of 1-6 carbon atoms, aryl of 6-10 carbon atoms, arylalkyl of 7-15 carbon atoms, cycloalkyl of 3-8 carbon atoms, phthalic acid,
  • R 9 is CO 2 R 12 , CONHR 12 , tetrazole, PO 3 R 12 ;
  • R 10 is hydrogen, alkyl of 1-6 carbon atoms, aryl of 6-12 carbon atoms, aralkyl of 7-15 carbon atoms;
  • R 1 is alkylene of 1 to 3 carbon atoms
  • R 12 is hydrogen, alkyl of 1-6 carbon atoms, aryl of 6-12 carbon atoms, aralkyl of 7-15 carbon atoms;
  • X is O, or S
  • Y is O, N, or S
  • Z is C, or N
  • Pharmaceutically acceptable salts can be formed from organic and inorganic acids, for example, acetic, propionic, lactic, citric, tartaric, succinic, fumaric, maleic, malonic, mandelic, malic, phthalic, hydrochloric, hydrobromic, phosphoric, nitric, sulfuric, methanesulfonic, napthalenesulfonic, benzenesulfonic, toluenesulfonic, camphorsulfonic, and similarly known acceptable acids when a compound of this invention contains a basic moiety.
  • organic and inorganic acids for example, acetic, propionic, lactic, citric, tartaric, succinic, fumaric, maleic, malonic, mandelic, malic, phthalic, hydrochloric, hydrobromic, phosphoric, nitric, sulfuric, methanesulfonic, napthalenesulfonic, benzenesulfonic, toluenesulf
  • Salts may also be formed from organic and inorganic bases, preferably alkali metal salts, for example, sodium, lithium, or potassium, when a compound of this invention contains a carboxylate or phenolic moiety, or similar moiety capable of forming base addition salts.
  • alkali metal salts for example, sodium, lithium, or potassium
  • Alkyl includes both straight chain as well as branched moieties.
  • Halogen means bromine, chlorine, fluorine, and iodine.
  • the aryl portion of the aryl or aralkyl substituent is a phenyl, naphthyl or l,4-benzodioxan-5-yl group; with phenyl being most preferred.
  • the aryl moiety may be optionally mono-, di-, or tri- substituted with a substituent selected from the group consisting of alkyl of 1-6 carbon atoms, alkoxy of 1-6 carbon atoms, trifluoromethyl, halogen, alkoxycarbonyl of 2-7 carbon atoms, alkylamino of 1-6 carbon atoms, and dialkylamino in which each of the alkyl groups is of 1-6 carbon atoms, nitro, cyano, -CO 2 H, alkylcarbonyloxy of 2-7 carbon atoms, and alkylcarbonyl of 2-7 carbon atoms.
  • the compounds of this invention may contain an asymmetric carbon atom and some of the compounds of this invention may contain one or more asymmetric centers and may thus give rise to optical isomers and diastereomers. While shown without respect to stereochemistry in Formula I, the present invention includes such optical isomers and diastereomers; as well as the racemic and resolved, enantiomerically pure R and S stereoisomers; as well as other mixtures of the R and S stereoisomers and pharmaceutically acceptable salts thereof.
  • Preferred compounds of this invention are those compounds of Formula I, X is oxygen. More preferred compouds of this invention are those compounds of of Formula I, wherein: X is O;
  • R 1 is phenyl substituted with R 6 ;
  • R 2 is alkyl of 1-6 carbon atoms
  • R 3 and R 4 are each, independently, hydrogen or halogen.
  • the compounds of this invention can be prepared according to the following schemes from commercially available starting materials or starting materials which can be prepared using to literature procedures. These Schemes show the preparation of representative compounds of this invention.
  • Oxazoles (3) were coupled with aryl boronic acids of general structure (4; R 3 , R 4 are alkyl, aryl, trifluoromethyl, substituted aryl, nitro, carbocyclic 5 to 7 carbon atoms rings or heterocyclic rings 5 to 7 atom rings with from 1 to 3 heteroatoms selected from oxygen, nitrogen, and sulfur) using the Suzuki protocol [ref. Syn. Comm. 1981, 11, 513-519] to produce biphenyls (5).
  • the aryl boronic acids are either commercially available or can be prepared according to known methodology [ref. J. Org. Chem, 1984, 49, 5237-5243].
  • Biphenyls (5) converted to phenols (6) by treatment with boron tribromide in dichloromethane [ref. J. Org. Chem. 1974, 39, 1427-1429].
  • Phenols (6) were alkylated with bromo or chloro-alkylcarboxylates [(Br or Cl)(CH 2 ) n CO 2 R 12 ] in the presence of sodium hydride or potassium carbonate, using dimethylformamide or acetonitrile as the solvent. Subsequent saponification with sodium hydroxide in methyl alcohol and tetrahydrofuran produced biphenyls (7).
  • thiazoles (10) were brominated with bromine in the presence of sodium acetate.
  • the 4-bromo-thiazoles (11) were coupled with 4, 4'-methoxy biphenyl boronic acid using the Suzuki protocol [ref. Syn. Comm. 1981, 11, 513-519] to give biphenyls (12).
  • Biphenyls (12) were further converted to the desired products in substantially the same manner as described in Scheme I.
  • the biphenyl compounds (13 ) can be monobrominated or dibrominated using bromine, potassium acetate and acetic acid.
  • the Suzuki coupling protocol [ref. Syn. Comm. 1981, 11, 513-519] was used to generate the terphenyls 15 and 16.
  • heterocyclic boronic acids for example thiophene, furan, oxazole, thiazole, pyridine.
  • oxazoles (3) were coupled with aryl boronic acids of general structure (4; R 3 , R 4 are alkyl, aryl, trifluoromethyl, substituted aryl, nitro, carbocyclic 5 to 7 carbon atoms rings or heterocyclic rings 5 to 7 atom rings with from 1 to 3 heteroatoms selected from oxygen, nitrogen, and sulfur) using the Suzuki protocol [ref. Syn. Comm. 1981, 11, 513-519] to produce biphenyls (17).
  • Biphenyls (17) were converted to oximes (18) with hydroxylamine in the presence of sodium acetate.
  • Oximes (18) were reduced with sodium cyanoborohydride under acidic conditions to produce to hydroxylamines (19).
  • hydroxylamines (19) were treated with N- (chlorocarbonyl)isocyanate to produce oxadiazolidinediones (20).
  • Thiazolidinediones were prepared from benzaldehydes (17) using known methodology [ref. J. Med. Chem., 1992, 35, 1853-1864].
  • the compounds of this invention are useful in treating metabolic disorders related to insulin resistance or hyperglycemia, typically associated with obesity or glucose intolerance.
  • the compounds of this invention are therefore, particularly useful in the treatment or inhibition of type II diabetes.
  • the compounds of this invention are also useful in modulating glucose levels in disorders such as type I diabetes.
  • This standard pharmacological test procedure assess the inhibition of rat hepatic microsomal PTPase activity using, as substrate, the phosphotyrosyl dodecapeptide corresponding to the 1142-1153 insulin receptor kinase domain, phosphorylated on the
  • Rats (Male Sprague-Dawley rats (Charles River, Springfield, NY) weighing 100-150 g, maintained on standard rodent chow (Purina)) are sacrificed by asphyxiation with CO2 and bilateral thoracotomy. The liver is removed and washed in cold 0.85% (w/v) saline and weighed. The tissue is homogenized on ice in 10 volumes of Buffer A and the microsomes are isolated essentially as described by Meyerovitch J, Rothenberg P, Shechter Y, Bonner-Weir S, Kahn CR. Vanadate normalizes hyperglycemia in two mouse models of non-insulin-dependent diabetes mellitus.
  • liver homogenate is filtered through silk to remove any remaining tissue debris and then is centrifuged at 10,000xg for 20 minutes at 40C. The supernatant is decanted and centrifuged at 100,000xgfor 60 minutes at 40C.
  • the pellet, microsomes and small vesicles is resuspended and lightly homogenized in : 20 mM TRIS-HC1 (pH 7.4), 50 mM 2-mercaptoethanol, 250 mM sucrose, 2 mM EDTA, 10 mM EGTA, 2 mM AEBSF, 0.1 mM TLCK, 0.1 mM TPCK, 0.5 mM benzamidine, 25 ug/ml leupeptin, 5 ug/ml pepstatin A, 5 ug/ml;H5B antipain, 5 ug/ml chymostatin, 10 ug/ml aprotinin (Buffer A), to a final concentration of approximately 850 ug protein/ml. Protein concentration is determined by the Pierce Coomassie Plus Protein Assay using crystalline bovine serum albumin as a standard (Pierce Chemical Co., Rockford, IL).
  • the microsomal fraction (83.25 ul) is preincubated for 10 min at 37deg.C with or without test compound (6.25ul) and 305.5 ul of the 81.83 mM HEPES reaction buffer, pH 7.4.
  • Peptide substrate, 10.5 ul at a final concentration of 50 uM, is equilibrated to 37deg.C in a LABLINE Multi-Blok heater equipped with a titerplate adapter.
  • the preincubated microsomal preparation (39.5 ul) with or without drug is added to initiate the dephosphorylation reaction, which proceeds at 37deg.C for 30 min.
  • the reaction is terminated by the addition of 200 ul of the malachite green- ammonium molybdate-Tween 20 stopping reagent (MG/AM/Tw).
  • the stopping reagent consists of 3 parts 0.45% malachite green hydrochloride, 1 part 4.2% ammonium molybdate tetrahydrate in 4 N HCI and 0.5% Tween 20.
  • Sample blanks are prepared by the addition of 200 ul MG/AM/Tw to substrate and followed by 39.5 ul of the preincubated membrane with or without drug.
  • sample absorbances are determined at 650 nm using a platereader (Molecular Devices). Samples and blanks are prepared in quadruplicates. Screening activity of 50 uM (final) drug is accessed for inhibition of microsomal PTPases.
  • PTPase activities based on a potassium phosphate standard curve, are expressed as nmoles of phosphate released/min/mg protein. Test compound PTPase inhibition is calculated as percent of control. A four parameter non-linear logistic regression of PTPase activities using SAS release 6.08, PROC NLIN, is used for determining IC50 values of test compounds. All compounds were administered at a concentration of 50 uM. The following results were obtained using representative compounds of this invention.
  • This standard pharmacological test procedure assess the inhibition of recombinant rat protein tyrosine phosphatase, PTP1B, activity using, as substrate, the phosphotyrosyl dodecapeptide corresponding to the 1142-1153 insulin receptor kinase domain, phosphorylated on the 1146, 1150 and 1151 tyrosine residues.
  • the procedure used and results obtained are briefly described below.
  • Human recombinant PTP1B was prepared as described by Goldstein (see Goldstein et al. Mol. Cell. Biochem. 109, 107, 1992).
  • the enzyme preparation used was in microtubes containing 500-700 ⁇ g/ml protein in 33 mM Tris-HCl, 2 mM EDTA, 10% glycerol and 10 mM 2-mercaptoethanol.
  • the malachite green-ammonium molybdate method as described (Lanzetta et al. Anal. Biochem. 100, 95, 1979) and adapted for a platereader, is used for the nanomolar detection of liberated phosphate by recombinant PTP1B.
  • the test procedure uses, as substrate, a dodecaphosphopeptide custom synthesized by AnaSpec, Inc. (San Jose, CA).
  • the peptide, TRDIYETDYYRK corresponding to the 1142-1153 catalytic domain of the insulin receptor, is tyrosine phosphorylated on the 1146, 1150, and 1151 tyrosine residues.
  • the recombinant rPTPlB is diluted with buffer (pH 7.4, containing 33 mM Tris-HCl, 2 mM EDTA and 50 mM b-mercaptoethanol) to obtain an approximate activity of 1000- 2000 nmoles/min/mg protein.
  • the diluted enzyme (83.25 mL) is preincubated for 10 min at 37°C with or without test compound (6.25 mL) and 305.5 mL of the 81.83 mM HEPES reaction buffer, pH 7.4 peptide substrate, 10.5 ml at a final concentration of 50 mM, and is equilibrated to 37°C. in a LABLINE Multi-Blok heater equipped with a titerplate adapter.
  • the preincubated recombinant enzyme preparation (39.5 ml) with or without drug is added to initiate the dephosphorylation reaction, which proceeds at
  • the reaction is terminated by the addition of 200 mL of the malachite green-ammonium molybdate-Tween 20 stopping reagent (MG/AM/Tw).
  • the stopping reagent consists of 3 parts 0.45% malachite green hydrochloride, 1 part 4.2% ammonium molybdate tetrahydrate in 4 N HCI and 0.5% Tween 20.
  • Sample blanks are prepared by the addition of 200 mL MG/AM/Tw to substrate and followed by 39.5 ml of the preincubated recombinant enzyme with or without drug. The color is allowed to develop at room temperature for 30 min. and the sample absorbances are determined at 650 nm using a platereader (Molecular Devices). Sample and blanks are prepared in quadruplicates.
  • PTPase activities based on a potassium phosphate standard curve, are expressed as nmoles of phosphate released/min/mg protein. Inhibition of recombinant PTP1B by test compounds is calculated as percent of phosphatase control.
  • the non-insulin dependent diabetic (NIDDM) syndrome can be typically characterizes by obesity, hyperglycemia, abnormal insulin secretion, hyperinsulinemia and insulin resistance.
  • the genetically obese-hyperglycemic ob/ob mouse exhibits many of these metabolic abnormalities and is thought to be a useful model to search for hypoglycemic agents to treat NIDDM [Coleman, D.: Diabetologia 14: 141-148, 1978].
  • mice [Male or female ob/ob (C57 B1/6J) and their lean litermates (ob/+ or +/+, Jackson Laboratories) ages 2 to 5 months (10 to 65 g)] of a similar age were randomized according to body weight into 4 groups of 10 mice. The mice were housed 5 per cage and are maintained on normal rodent chow with water ad libitum. Mice received test compound daily by gavage (suspended in 0.5 ml of 0.5% methyl cellulose); dissolved in the drinking water; or admixed in the diet. The dose of compounds given ranges from 2.5 to 200 mg/kg body weight/day. The dose is calculated based on the fed weekly body weight and is expressed as active moiety.
  • mice received vehicle only.
  • Statistically (p ⁇ 0.05) significant Based on the results obtained in the standard pharmacological test procedures, representative compounds of this invention have been shown to inhibit PTPase activity and lower blood glucose levels in diabetic mice, and are therefore useful in treating metabolic disorders related to insulin resistance or hyperglycemia, typically associated with obesity or glucose intolerance. More particularly, the compounds of this invention useful in the treatment or inhibition of type II diabetes, and in modulating glucose levels in disorders such as type I diabetes. As used herein, the term modulating means maintaining glucose levels within clinically normal ranges.
  • Effective administration of these compounds may be given at a daily dosage of from about 1 mg kg to about 250 mg/kg, and may given in a single dose or in two or more divided doses. Such doses may be administered in any manner useful in directing the active compounds herein to the recipient's bloodstream, including orally, via implants, parenterally (including intravenous, intraperitoneal and subcutaneous injections), rectally, vaginally, and transdermally.
  • transdermal administrations are understood to include all administrations across the surface of the body and the inner linings of bodily passages including epithelial and mucosal tissues.
  • Such administrations may be carried out using the present compounds, or pharmaceutically acceptable salts thereof, in lotions, creams, foams, patches, suspensions, solutions, and suppositories (rectal and vaginal).
  • Oral formulations containing the active compounds of this invention may comprise any conventionally used oral forms, including tablets, capsules, buccal forms, troches, lozenges and oral liquids, suspensions or solutions.
  • Capsules may contain mixtures of the active compound(s) with inert fillers and/or diluents such as the pharmaceutically acceptable starches (e.g. corn, potato or tapioca starch), sugars, artificial sweetening agents, powdered celluloses, such as crystalline and microcrystalline celluloses, flours, gelatins, gums, etc.
  • Useful tablet formulations may be made by conventional compression, wet granulation or dry granulation methods and utilize pharmaceutically acceptable diluents, binding agents, lubricants, disintegrants, suspending or stabilizing agents, including, but not limited to, magnesium stearate, stearic acid, talc, sodium lauryl sulfate, microcrystalline cellulose, carboxymethyl- cellulose calcium, polyvinylpyrrolidone, gelatin, alginic acid, acacia gum, xanthan gum, sodium citrate, complex silicates, calcium carbonate, glycine, dextrin, sucrose, sorbitol, dicalcium phosphate, calcium sulfate, lactose, kaolin, mannitol, sodium chloride, talc, dry starches and powdered sugar.
  • pharmaceutically acceptable diluents including, but not limited to, magnesium stearate, stearic acid, talc, sodium lauryl sulfate, micro
  • Oral formulations herein may utilize standard delay or time release formulations to alter the absorption of the active compound(s).
  • Suppository formulations may be made from traditional materials, including cocoa butter, with or without the addition of waxes to alter the suppository's melting point, and glycerin.
  • Water soluble suppository bases such as polyethylene glycols of various molecular weights, may also be used.
  • the dosage, regimen and mode of administration of these compounds will vary according to the malady and the individual being treated and will be subject to the judgment of the medical practitioner involved. It is preferred that the administration of one or more of the compounds herein begin at a low dose and be increased until the desired effects are achieved.
  • Step b) 4-(4-Bromo-phenyl)-5-methyl-2-(4-trifluoromethyl-phenyl)-oxazole
  • Step c) 4-(4 , -methoxy-biphenyl-4-ylV5-methyl-2-(4-trifluoromethyl-phenyl)-oxazole 4-Methoxy-benzeneboronic acid (1.44 g, 7.19 mmol) in ethyl alcohol (5 mL) was added into a mixture of 4-(4-bromo-phenyl)-5-methyl-2-(4-trifluoromethyl- phenyl)-oxazole (2.5 g, 6.54mmol), sodium carbonate (2N, 6.5 mL), tetrakis- (triphenylphosphine)palladium(O) (0.23 g, 0.196 mmol), and toluene (200 mL).
  • the title compound was prepared from 4-(4-bromo-phenyl)-5-methyl-2-(4- trifluoromethyl-phenyl)-oxazole, and 4-methoxy-benzeneboronic acid in substantially the same manner, as described in Example 1 step c, and was obtained as a white solid, mp 93-94 °C; MS m/e 409 (M + );
  • the title compound was prepared from 4-(4'-methoxy-biphenyl-3-yl)-5-methyl- 2-(4-trifluoromethyl-phenyl)-oxazole, in substantially the same manner, as described in Example 3, and was obtained as a white solid, mp 133-135 °C; MS m/e 395 (M + );
  • reaction mixture was stirred for 30 minutes, poured into water, acidified with HCI
  • Example 7 and was obtained as a white solid, mp 148-149 °C; MS m/e 543 (M + ); Analysis for: C 32 H 24 F 3 NO 4 Calc'd: C, 70.71; H, 4.45; N, 2.58 Found: C, 70.72; H ,
  • This compound was prepared from 4-(4-bromo-phenyl)-5-methyl-2-(4- trifluoromethyl-phenyl)-oxazole, and 4-formylbenzeneboronic acid in substantially the same manner, as described in Example 1 step c, and was obtained as an off-white solid;
  • This compound was prepared from 4'-[5-methyl-2-(4-trifluoromethyl-phenyl)- oxazol-4-yl]-biphenyl-4-carbaldehyde, and hydroxylamine in substantially the same manner, as described in Example 1 step a, and was obtained as an off-white solid; MS m/e 422 (M + );
  • N-(Chlorocarbonyl)isocyanate (0.2 mL, 2.6 mmol) was added dropwise into a cold (-5 °Q mixture of N- ⁇ 4'-[5-methyl-2-(4-trifluoromethyl-phenyl)-oxazol-4-yl]- biphenyl-4-ylmethyl ⁇ -hydroxylamine (1.1, 2.6 mmol), and tetrahydrofuran (20.0 mL).
  • reaction mixture was stirred for 30 minutes, poured into water, acidified with HCI
  • This compound was prepared from 3-(4-bromo-phenyl)-5-methyl-2-(4- trifluoromethyl-phenyl)-oxazole in substantially the same manner, as described in
  • Example 1 steps a-d, and was obtained as a white solid, mp 216-218; MS m/e 493 (M + );
  • This compound was prepared from l-(6-methoxy-naphthalen-2-yl)propanone oxime, and 4-trifluoromethyl-phenyl acetyl chloride in substantially the same manner, as described in Example 1 steps b, and was obtained as a white solid, mp 138-139; MS m/e 383 (M + ); Analysis for: C 22 H 19 F 3 NO 2 Calc'd: C, 68.93; H, 4.21; N, 3.65 Found: C, 68.83; H,
  • This compound was prepared from 4'-(6-methoxy-naphthalen-2-yl)-5-methyl- 2-(4-trifluoromethyl-phenyl)-oxazole and boron tribromide in substantially the same manner, as described in Example 3, and was obtained as a white solid, mp 188-191; MS m/e 370 (M+H) + ;
  • This compound was prepared from 4'-(6-hydroxy-naphthalen-2-yl)-5-methyl-2- (4-trifluoromethyl-phenyl)-oxazole and bromine in substantially the same manner, as described in Example 9, and was obtained as an off-white solid; MS m/e 447 (M + ); Analysis for: C 21 H 13 BrF 3 NO 2 Calc'd: C, 56.27; H, 2.92; N, 3.12 Found: C, 56.20; H, 2.66; N, 3.15
  • This compound was prepared from 4'-(5-bromo-6-hydroxy-naphthalen-2-yl)-5- methyl-2-(4-trifluoromethyl-phenyl)-oxazole and methyl bromoacetate in substantially the same manner, as described in Example 5, and was obtained as white solid, mp 212- 214 °C; MS m/e 506 (M+H) + ; Analysis for: C 23 H 15 BrF 3 NO 4 Calc'd: C, 54.57; H, 2.99; N, 2.77 Found: C, 54.17; H, 2.69; N, 2.76
  • This compound was prepared from 4'-(5-bromo-6-hydroxy-naphthalen-2-yl)-5- methyl-2-(4-trifluoromethyl-phenyl)-oxazole and methyl bromoacetate in substantially the same manner, as described in Example 7, and was obtained as an off-white solid, mp 195-197 °C; MS m/e 596 (M+H) + ; Analysis for: C 30 H 21 BrF 3 NO 4 Calc'd: C, 60.42; H, 3.55; N, 2.35 Found: C, 60.31; H,

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

This invention provides compounds of Formula (I) having the structure (I) wherein R is (a) or (b); A is OR5, or (c); R1 is alkyl of 1-6 carbon atoms, cycloalkyl of 3-8 carbon atoms, thienyl, furyl, pyridyl, (d) or (e) R2 is hydrogen, alkyl of 1-6 carbons atoms, or aryl of 6 to 10 carbon atoms; R?3 and R4¿ are independently halogen, hydrogen, alkyl of 1-12 carbon atoms, aryl of 6 to 10 carbon atoms; halogen, trifluoromethyl of 1-6 carbon atoms, alkoxyaryl of 7-14 carbon atoms; nitro, amino, carboalkoxy, carbamide, carbamate, urea, alkylsulfoamide, -NR7(CH2)mO2H, arylsulfoamide, cycloalkyl of 3-8 carbon atoms, or heterocycle of 5 to 7 atom rings containing from 1 to 3 heteroatoms selected from oxygen, nitrogen, or sulfur; R5 is hydrogen, alkyl of 1-6 carbon atoms, -CH(R8)R9, -C(CH¿2?)nCO2R?10¿, -C(CH¿3?)2CO2R?10, -CH(R8)(CH¿2)nCO2R?10, -CH(R8)C¿6H4CO2R10, or -CH¿2?-tetrazole; R?6¿ is hydrogen, alkyl of 1-6 carbon atoms, halogen, alkyoxy of 1-6 carbon atoms, trifluoroalkyl of 1-6 carbon atoms or trifluoroalkoxy of 1-6 carbon atoms; or a pharmaceutically acceptable salt thereof, which are useful in treating metabolic disorders related to insulin resistance or hyperglycemia.

Description

OXAZOLE-ARYL-CARBOXYLIC ACIDS USEFUL IN THE TREATMENT OF INSULIN RESISTANCE AND HYPERGLYCEMIA
BACKGROUND OF THE INVENTION
The prevalence of insulin resistance in glucose intolerant subjects has long been recognized. Reaven et al (American Journal of Medicine 1976, 60, 80) used a continuous infusion of glucose and insulin (insulin/glucose clamp technique) and oral glucose tolerance tests to demonstrate that insulin resistance existed in a diverse group of nonobese, nonketotic subjects. These subjects ranged from borderline glucose tolerant to overt, fasting hyperglycemia. The diabetic groups in these studies included both insulin dependent (IDDM) and noninsulin dependent (NIDDM) subjects.
Coincident with sustained insulin resistance is the more easily determined hyperinsulinemia, which can be measured by accurate determination of circulating plasma insulin concentration in the plasma of subjects. Hyperinsulinemia can be present as a result of insulin resistance, such as is in obese and/or diabetic (NIDDM) subjects and/or glucose intolerant subjects, or in IDDM subjects, as a consequence of over injection of insulin compared with normal physiological release of the hormone by the endocrine pancreas. The association of hyperinsulinemia with obesity and with ischemic diseases of the large blood vessels (e.g. atherosclerosis) has been well established by numerous experimental, clinical and epidemiological studies (summarized by Stout, Metabolism 1985, 34, 1, and in more detail by Pyorala et al, Diabetes/Metabolism Reviews 1987, 3, 463). Statistically significant plasma insulin elevations at 1 and 2 hours after oral glucose load correlates with an increased risk of coronary heart disease.
Since most of these studies actually excluded diabetic subjects, data relating the risk of atherosclerotic diseases to the diabetic condition are not as numerous, but point in the same direction as for nondiabetic subjects (Pyorala et al). However, the incidence of atherosclerotic diseases in morbidity and mortality statistics in the diabetic population exceeds that of the nondiabetic population (Pyorala et al; Jarrett Diabetes/Metabolism Reviews 1989,5, 547; Harris et al, Mortality from diabetes, in Diabetes in America 1985).
The independent risk factors obesity and hypertension for atherosclerotic diseases are also associated with insulin resistance. Using a combination of insulin/glucose clamps, tracer glucose infusion and indirect calorimetry, it has been demonstrated that the insulin resistance of essential hypertension is located in peripheral tissues (principally muscle) and correlates directly with the severity of hypertension (DeFronzo and Ferrannini, Diabetes Care 1991, 14, 173). In hypertension of the obese, insulin resistance generates hyperinsulinemia, which is recruited as a mechanism to limit further weight gain via thermogenesis, but insulin also increases renal sodium reabsorption and stimulates the sympathetic nervous system in kidneys, heart, and vasculature, creating hypertension.
It is now appreciated that insulin resistance is usually the result of a defect in the insulin receptor signaling system, at a site post binding of insulin to the receptor. Accumulated scientific evidence demonstrating insulin resistance in the major tissues which respond to insulin (muscle, liver, adipose), strongly suggests that a defect in insulin signal transduction resides at an early step in this cascade, specifically at the insulin receptor kinase activity, which appears to be diminished (reviewed by Haring, Diabetalogia 1991, 34, 848).
Protein-tyrosine phosphatases (PTPases) play an important role in the regulation of phosphorylation of proteins. The interaction of insulin with its receptor leads to phosphorylation of certain tyrosine molecules within the receptor protein, thus activating the receptor kinase. PTPases dephosphorylate the activated insulin receptor, attenuating the tyrosine kinase activity. PTPases can also modulate post-receptor signaling by catalyzing the dephosphorylation of cellular substrates of the insulin receptor kinase. The enzymes that appear most likely to closely associate with the insulin receptor and therefore, most likely to regulate the insulin receptor kinase activity, include PTP1B, LAR, PTPα and SH-PTP2 (B. J. Goldstein, J. Cellular Biochemistry 1992, 48, 33; B. J. Goldstein, Receptor 1993, 3, 1-15,; F. Ahmad and B. J. Goldstein Biochim. Biophys Acta 1995, 1248, 57-69). McGuire et al. (Diabetes 1991, 40, 939), demonstrated that nondiabetic glucose intolerant subjects possessed significantly elevated levels of PTPase activity in muscle tissue vs. normal subjects, and that insulin infusion failed to suppress PTPase activity as it did in insulin sensitive subjects.
Meyerovitch et al (J. Clinical Invest. 1989, 84, 976) observed significantly increased PTPase activity in the livers of two rodent models of IDDM, the genetically diabetic BB rat, and the STZ-induced diabetic rat. Sredy et al (Metabolism, 44, 1074, 1995) observed similar increased PTPase activity in the livers of obese, diabetic ob/ob mice, a genetic rodent model of NIDDM.
The compounds of this invention have been shown to inhibit PTPases derived from rat liver microsomes and human-derived recombinant PTPase- IB (hPTP-lB) in vitro. They are useful in the treatment of insulin resistance associated with obesity, glucose intolerance, diabetes mellitus, hypertension and ischemic diseases of the large and small blood vessels.
DESCRIPTION OF THE INVENTION
This invention provides a compound of formula I having the structure
wherein
R1 is alkyl of 1-6 carbon atoms, cycloalkyl of 3-8 carbon atoms, thienyl, furyl, pyridyl,
R2 is hydrogen, alkyl of 1-6 carbon atoms, or aryl of 6 to 10 carbon atoms;
R3 and R4 are independently halogen, hydrogen, alkyl of 1-12 carbon atoms , aryl of 6 to 10 carbon atoms; halogen, trifluoromethylof 1-6 carbon atoms, alkoxyaryl of
7-14 carbon atoms; nitro, amino, carboalkoxy, carbamide, carbamate, urea, alkylsulfoamide, -NR7(CH2)rnCO2H, arylsulfoamide, cycloalkyl of 3-8 carbon atoms, or heterocycle of 5 to 7 atom rings containing from 1 to 3 heteroatoms selected from oxygen, nitrogen, or sulfur; R5 is hydrogen, alkyl of 1-6 carbon atoms, -CH(R8)R9, -C(CH2)nCO2R10,
-C(CH3)2CO2R10, -CH(R8)(CH2)nCO2RlO, -CH(R8)C6H4CO2RlO, or -CH2- tetrazole;
R6 is hydrogen, alkyl of 1-6 carbon atoms, halogen, alkyoxy of 1-6 carbon atoms, trifluoroalkyl of 1-6 carbon atoms or trifluoroalkoxy of 1-6 carbon atoms;
R7 is hydrogen or alkyl of 1 to 6 carbon atoms;
R8 is hydrogen, alkyl of 1-6 carbon atoms, aryl of 6-10 carbon atoms, arylalkyl of 7-15 carbon atoms, cycloalkyl of 3-8 carbon atoms, phthalic acid,
R9 is CO2R12, CONHR12, tetrazole, PO3R12;
R10is hydrogen, alkyl of 1-6 carbon atoms, aryl of 6-12 carbon atoms, aralkyl of 7-15 carbon atoms;
R1 ] is alkylene of 1 to 3 carbon atoms;
R12is hydrogen, alkyl of 1-6 carbon atoms, aryl of 6-12 carbon atoms, aralkyl of 7-15 carbon atoms;
X is O, or S;
Y is O, N, or S;
Z is C, or N;
Q is O, N, or S; m = l-3; n = 1-6, or a pharmaceutically acceptable salt thereof, which are useful in treating metabolic disorders related to insulin resistance or hyperglycemia.
Pharmaceutically acceptable salts can be formed from organic and inorganic acids, for example, acetic, propionic, lactic, citric, tartaric, succinic, fumaric, maleic, malonic, mandelic, malic, phthalic, hydrochloric, hydrobromic, phosphoric, nitric, sulfuric, methanesulfonic, napthalenesulfonic, benzenesulfonic, toluenesulfonic, camphorsulfonic, and similarly known acceptable acids when a compound of this invention contains a basic moiety. Salts may also be formed from organic and inorganic bases, preferably alkali metal salts, for example, sodium, lithium, or potassium, when a compound of this invention contains a carboxylate or phenolic moiety, or similar moiety capable of forming base addition salts.
Alkyl includes both straight chain as well as branched moieties. Halogen means bromine, chlorine, fluorine, and iodine. It is preferred that the aryl portion of the aryl or aralkyl substituent is a phenyl, naphthyl or l,4-benzodioxan-5-yl group; with phenyl being most preferred. The aryl moiety may be optionally mono-, di-, or tri- substituted with a substituent selected from the group consisting of alkyl of 1-6 carbon atoms, alkoxy of 1-6 carbon atoms, trifluoromethyl, halogen, alkoxycarbonyl of 2-7 carbon atoms, alkylamino of 1-6 carbon atoms, and dialkylamino in which each of the alkyl groups is of 1-6 carbon atoms, nitro, cyano, -CO2H, alkylcarbonyloxy of 2-7 carbon atoms, and alkylcarbonyl of 2-7 carbon atoms.
The compounds of this invention may contain an asymmetric carbon atom and some of the compounds of this invention may contain one or more asymmetric centers and may thus give rise to optical isomers and diastereomers. While shown without respect to stereochemistry in Formula I, the present invention includes such optical isomers and diastereomers; as well as the racemic and resolved, enantiomerically pure R and S stereoisomers; as well as other mixtures of the R and S stereoisomers and pharmaceutically acceptable salts thereof.
Preferred compounds of this invention are those compounds of Formula I, X is oxygen. More preferred compouds of this invention are those compounds of of Formula I, wherein: X is O;
R1 is phenyl substituted with R6;
R2 is alkyl of 1-6 carbon atoms; and
R3 and R4 are each, independently, hydrogen or halogen.
Specifically preferred compounds of the present invention are set forth below:
4-(4'-methoxy-biphenyl-4-yl)-5-methyl-2-(4-trifluoromethyl-phenyl)-oxazole
4-(4'-methoxy-biphenyl-3-yl)-5-methyl-2-(4-trifluoromethyl-phenyl)-oxazole 4'-[5-methyl-2-(4-trifluoromethyl-phenyl)-oxazol-4-yl]-biphenyl-4-ol
3'-[5-methyl-2-(4-trifluoromethyl-phenyl)-oxazol-4-yl]-biphenyl-4-ol
{ 4' -[5-methyl-2-(4-trifluoromethyl-phenyl)-oxazol-4-yl]-biphenyl-4-yloxy } -acetic acid
{ 3 ' - [5-methyl-2-(4-trifluoromethyl-phenyl)-oxazol-4-yl] -biphenyl-4-yloxy } -acetic acid
2-{4'-[5-methyl-2-(4-trifluoromethyl-phenyl)-oxazol-4-yl]-biphenyl-4-yloxy}-3- phenyl-propionic acid
2-{3'-[5-methyl-2-(4-trifluoromethyl-phenyl)-oxazol-4-yl]-biphenyl-4-yloxy}-3- phenyl-propionic acid
3,5-dibromo-4'-[5-methyl-2-(4-trifluoromethyl-phenyl)-oxazol-4-yl]-biphenyl-4-ol
{3,5-dibromo-4'-[5-methyl-2-(4-trifluoromethyl-phenyl)-oxazol-4-yl]-biphenyl-4- yloxy} -acetic acid
2-{3,5-dibromo-4'-[5-methyl-2-(4-trifluoromethyl-phenyl)-oxazol-4-yl]-biphenyl-4- yloxy}-3-phenyl-propionic acid methyl ester
2-{3,5-dibromo-4'-[5-methyl-2-(4-trifluoromethyl-phenyl)-oxazol-4-yl]-biphenyl-4- yloxy}-3-phenyl-propionic acid
2- { 4' - [5-methyl-2-(4-trifluoromethyl-phenyl)-oxazol-4-yl] -bipheny 1-4-ylmethyl } - [l,2,4]oxadiazolidine-3,5-dione
2-{4'-[5-methyl-2-(4-trifluoromethyl-phenyl)-oxazol-4-yl]-biphenyl-3-ylmethyl}- [l,2,4]oxadiazolidine-3,5-dione
5-{4'-[5-methyl-2-(4-trifluoromethyl-phenyl)-oxazol-4-yl]-biphenyl-4-yloxymethyl}- lH-tetrazole
or a pharmaceutically acceptable salt thereof. The compounds of this invention can be prepared according to the following schemes from commercially available starting materials or starting materials which can be prepared using to literature procedures. These Schemes show the preparation of representative compounds of this invention.
Scheme I
In Scheme I commercially available ketones (1) were treated with hydroxylamine in the presence of sodium acetate to produce oximes (2). Oximes (2) were converted to oxazoles by a known methodology [ref. Tet. Lett. 1980, 21, 2359- 2360], where oximes (2) were treated with acetyl chlorides in the presence of pyridine to produce oxazoles (3). Oxazoles (3) were coupled with aryl boronic acids of general structure (4; R3, R4 are alkyl, aryl, trifluoromethyl, substituted aryl, nitro, carbocyclic 5 to 7 carbon atoms rings or heterocyclic rings 5 to 7 atom rings with from 1 to 3 heteroatoms selected from oxygen, nitrogen, and sulfur) using the Suzuki protocol [ref. Syn. Comm. 1981, 11, 513-519] to produce biphenyls (5). The aryl boronic acids are either commercially available or can be prepared according to known methodology [ref. J. Org. Chem, 1984, 49, 5237-5243]. Biphenyls (5) converted to phenols (6) by treatment with boron tribromide in dichloromethane [ref. J. Org. Chem. 1974, 39, 1427-1429]. Phenols (6) were alkylated with bromo or chloro-alkylcarboxylates [(Br or Cl)(CH2)nCO2R12] in the presence of sodium hydride or potassium carbonate, using dimethylformamide or acetonitrile as the solvent. Subsequent saponification with sodium hydroxide in methyl alcohol and tetrahydrofuran produced biphenyls (7). Coupling of biphenyls (6) with hydroxy-alkyl-carboxylates [HOCH(R8)CO2R12] using the Mitsunobu protocol [ref. Synthesis. 1981, 1-27], followed by saponification with sodium hydroxide in methyl alcohol and tetrahydrofuran produced biphenyls (8). Tetrazoles (9) were prepared from phenols (6) in a two step sequence. First the phenols (6) were alkylated with bromoacetonitrile in the presence of sodium hydride, and secondly, the nitrile was converted to tetrazoles (9) with sodium azide.
Scheme II
In Scheme II thiazoles (10) were brominated with bromine in the presence of sodium acetate. The 4-bromo-thiazoles (11) were coupled with 4, 4'-methoxy biphenyl boronic acid using the Suzuki protocol [ref. Syn. Comm. 1981, 11, 513-519] to give biphenyls (12). Biphenyls (12) were further converted to the desired products in substantially the same manner as described in Scheme I.
Scheme III
16
15
In Scheme III, the biphenyl compounds (13 ) can be monobrominated or dibrominated using bromine, potassium acetate and acetic acid. One equivalent of bromine in a high dilution reaction mixture and low temperatures in the range of 5-10 °C afforded predominantly the monobrominated product (14; R3, R4 = H, Br). The dibrominated product (14; R3, R4 = Br, Br) was obtained with two equivalents of bromine at room temperature. The Suzuki coupling protocol [ref. Syn. Comm. 1981, 11, 513-519] was used to generate the terphenyls 15 and 16. Coupling of the monobromo compounds (14; R\ R4 = H, Br) with boronic acids RI -Ar-B(OH)2 ; (R13 = halogen, trifluoromethyl, alkoxy, alkyl, nitro, amino, carboalkoxy) in the present of an inorganic base, for example K2CO3, or Ba(OH)2, and palladium (0 or II) catalyst, for example Pd(PPh3)4, Pd(OAc)2, or (dppf)PdCl2, produced terphenyls (15; R3 = H). Similarly, the dibromo compounds (14; R3, R4 = Br, Br) can undergo Suzuki coupling to afford either the di-coupled product (16) by using 2 equivalents of boronic acid at high temperatures (100 °C), or the mono-coupled-mono-bromo product (15; R3, R4 = Br, Aryl-R13). Both the bromo and dibromo compounds can afford in the same synthetic manner products with various heterocyclic boronic acids, for example thiophene, furan, oxazole, thiazole, pyridine.
Scheme IV
NH2OH. HCI NaBHaCN
NaOAc HCI
18
20
In Scheme IV oxazoles (3) were coupled with aryl boronic acids of general structure (4; R3, R4 are alkyl, aryl, trifluoromethyl, substituted aryl, nitro, carbocyclic 5 to 7 carbon atoms rings or heterocyclic rings 5 to 7 atom rings with from 1 to 3 heteroatoms selected from oxygen, nitrogen, and sulfur) using the Suzuki protocol [ref. Syn. Comm. 1981, 11, 513-519] to produce biphenyls (17). Biphenyls (17) were converted to oximes (18) with hydroxylamine in the presence of sodium acetate. Oximes (18) were reduced with sodium cyanoborohydride under acidic conditions to produce to hydroxylamines (19). The hydroxylamines (19) were treated with N- (chlorocarbonyl)isocyanate to produce oxadiazolidinediones (20). Thiazolidinediones were prepared from benzaldehydes (17) using known methodology [ref. J. Med. Chem., 1992, 35, 1853-1864].
The compounds of this invention are useful in treating metabolic disorders related to insulin resistance or hyperglycemia, typically associated with obesity or glucose intolerance. The compounds of this invention are therefore, particularly useful in the treatment or inhibition of type II diabetes. The compounds of this invention are also useful in modulating glucose levels in disorders such as type I diabetes.
The ability of compounds of this invention to treat or inhibit disorders related to insulin resistance or hyperglycemia was established with representative compounds of this invention in the following two standard pharmacological test procedures which measure the inhibition of PTPase.
Inhibition of tri-phosphorylated insulin receptor dodecaphosphopeptide dephosphorylation by rat hepatic protein-tyrosine phosphatases (PTPases)
This standard pharmacological test procedure assess the inhibition of rat hepatic microsomal PTPase activity using, as substrate, the phosphotyrosyl dodecapeptide corresponding to the 1142-1153 insulin receptor kinase domain, phosphorylated on the
1146, 1150 and 1151 tyrosine residues. The procedure used and results obtained are briefly outlined below.
Preparation of Microsomal Fraction: Rats (Male Sprague-Dawley rats (Charles River, Kingston, NY) weighing 100-150 g, maintained on standard rodent chow (Purina)) are sacrificed by asphyxiation with CO2 and bilateral thoracotomy. The liver is removed and washed in cold 0.85% (w/v) saline and weighed. The tissue is homogenized on ice in 10 volumes of Buffer A and the microsomes are isolated essentially as described by Meyerovitch J, Rothenberg P, Shechter Y, Bonner-Weir S, Kahn CR. Vanadate normalizes hyperglycemia in two mouse models of non-insulin-dependent diabetes mellitus. J Clin Invest 1991; 87:1286-1294 and Alberts B, Bray D, Lewis J, Raff M, Roberts K, Watson JD, editors. Molecular biology of the cell. New York: Garland Publishing, Inc., 1989 with minor modifications. The liver homogenate is filtered through silk to remove any remaining tissue debris and then is centrifuged at 10,000xg for 20 minutes at 40C. The supernatant is decanted and centrifuged at 100,000xgfor 60 minutes at 40C. The pellet, microsomes and small vesicles, is resuspended and lightly homogenized in : 20 mM TRIS-HC1 (pH 7.4), 50 mM 2-mercaptoethanol, 250 mM sucrose, 2 mM EDTA, 10 mM EGTA, 2 mM AEBSF, 0.1 mM TLCK, 0.1 mM TPCK, 0.5 mM benzamidine, 25 ug/ml leupeptin, 5 ug/ml pepstatin A, 5 ug/ml;H5B antipain, 5 ug/ml chymostatin, 10 ug/ml aprotinin (Buffer A), to a final concentration of approximately 850 ug protein/ml. Protein concentration is determined by the Pierce Coomassie Plus Protein Assay using crystalline bovine serum albumin as a standard (Pierce Chemical Co., Rockford, IL).
Measurement of PTPase activity: The malachite green-ammonium molybdate method, as described by Lanzetta PA, Alvarez LJ, Reinach PS, Candia OA was used. An improved assay for nanomolar amounts of inorganic phosphate. Anal. Biochem. 1979;100:95-91, and adapted for the platereader, is used for the nanomolar detection of liberated phosphate by rat hepatic microsomal PTPases. The test procedure uses, as substrate, a dodecaphosphopeptide custom synthesized by AnaSpec, Inc. (San Jose, CA). The peptide, TRDIYETDYYRK, corresponding to the 1142-1153 catalytic domain of the insulin receptor, is tyrosine phosphorylated on the 1146, 1150 and 1151 tyrosine residues. The microsomal fraction (83.25 ul) is preincubated for 10 min at 37deg.C with or without test compound (6.25ul) and 305.5 ul of the 81.83 mM HEPES reaction buffer, pH 7.4. Peptide substrate, 10.5 ul at a final concentration of 50 uM, is equilibrated to 37deg.C in a LABLINE Multi-Blok heater equipped with a titerplate adapter. The preincubated microsomal preparation (39.5 ul) with or without drug is added to initiate the dephosphorylation reaction, which proceeds at 37deg.C for 30 min. The reaction is terminated by the addition of 200 ul of the malachite green- ammonium molybdate-Tween 20 stopping reagent (MG/AM/Tw). The stopping reagent consists of 3 parts 0.45% malachite green hydrochloride, 1 part 4.2% ammonium molybdate tetrahydrate in 4 N HCI and 0.5% Tween 20. Sample blanks are prepared by the addition of 200 ul MG/AM/Tw to substrate and followed by 39.5 ul of the preincubated membrane with or without drug. The color is allowed to develop at room temperature for 30 min and the sample absorbances are determined at 650 nm using a platereader (Molecular Devices). Samples and blanks are prepared in quadruplicates. Screening activity of 50 uM (final) drug is accessed for inhibition of microsomal PTPases.
Calculations: PTPase activities, based on a potassium phosphate standard curve, are expressed as nmoles of phosphate released/min/mg protein. Test compound PTPase inhibition is calculated as percent of control. A four parameter non-linear logistic regression of PTPase activities using SAS release 6.08, PROC NLIN, is used for determining IC50 values of test compounds. All compounds were administered at a concentration of 50 uM. The following results were obtained using representative compounds of this invention.
Inhibition of Tri-Phosphorylated Insulin Receptor Dodecaphosphopeptide Dephosphorylation by hPTPlB
This standard pharmacological test procedure assess the inhibition of recombinant rat protein tyrosine phosphatase, PTP1B, activity using, as substrate, the phosphotyrosyl dodecapeptide corresponding to the 1142-1153 insulin receptor kinase domain, phosphorylated on the 1146, 1150 and 1151 tyrosine residues. The procedure used and results obtained are briefly described below. Human recombinant PTP1B was prepared as described by Goldstein (see Goldstein et al. Mol. Cell. Biochem. 109, 107, 1992). The enzyme preparation used was in microtubes containing 500-700 μg/ml protein in 33 mM Tris-HCl, 2 mM EDTA, 10% glycerol and 10 mM 2-mercaptoethanol.
Measurement of PTPase activity. The malachite green-ammonium molybdate method, as described (Lanzetta et al. Anal. Biochem. 100, 95, 1979) and adapted for a platereader, is used for the nanomolar detection of liberated phosphate by recombinant PTP1B. The test procedure uses, as substrate, a dodecaphosphopeptide custom synthesized by AnaSpec, Inc. (San Jose, CA). the peptide, TRDIYETDYYRK, corresponding to the 1142-1153 catalytic domain of the insulin receptor, is tyrosine phosphorylated on the 1146, 1150, and 1151 tyrosine residues. The recombinant rPTPlB is diluted with buffer (pH 7.4, containing 33 mM Tris-HCl, 2 mM EDTA and 50 mM b-mercaptoethanol) to obtain an approximate activity of 1000- 2000 nmoles/min/mg protein. The diluted enzyme (83.25 mL) is preincubated for 10 min at 37°C with or without test compound (6.25 mL) and 305.5 mL of the 81.83 mM HEPES reaction buffer, pH 7.4 peptide substrate, 10.5 ml at a final concentration of 50 mM, and is equilibrated to 37°C. in a LABLINE Multi-Blok heater equipped with a titerplate adapter. The preincubated recombinant enzyme preparation (39.5 ml) with or without drug is added to initiate the dephosphorylation reaction, which proceeds at
37°C for 30 min. The reaction is terminated by the addition of 200 mL of the malachite green-ammonium molybdate-Tween 20 stopping reagent (MG/AM/Tw). The stopping reagent consists of 3 parts 0.45% malachite green hydrochloride, 1 part 4.2% ammonium molybdate tetrahydrate in 4 N HCI and 0.5% Tween 20. Sample blanks are prepared by the addition of 200 mL MG/AM/Tw to substrate and followed by 39.5 ml of the preincubated recombinant enzyme with or without drug. The color is allowed to develop at room temperature for 30 min. and the sample absorbances are determined at 650 nm using a platereader (Molecular Devices). Sample and blanks are prepared in quadruplicates.
Calculations: PTPase activities, based on a potassium phosphate standard curve, are expressed as nmoles of phosphate released/min/mg protein. Inhibition of recombinant PTP1B by test compounds is calculated as percent of phosphatase control. A four parameter non-linear logistic regression of PTPase activities using SAS release 6.08, PROC NLIN, is used for determining IC50 values of test compounds. The following results were obtained.
The blood glucose lowering activity of representative compounds of this invention were demonstrated in an in vivo standard procedure using diabetic (ob/ob) mice. The procedures used and results obtained are briefly described below.
The non-insulin dependent diabetic (NIDDM) syndrome can be typically characterizes by obesity, hyperglycemia, abnormal insulin secretion, hyperinsulinemia and insulin resistance. The genetically obese-hyperglycemic ob/ob mouse exhibits many of these metabolic abnormalities and is thought to be a useful model to search for hypoglycemic agents to treat NIDDM [Coleman, D.: Diabetologia 14: 141-148, 1978]. In each test procedure, mice [Male or female ob/ob (C57 B1/6J) and their lean litermates (ob/+ or +/+, Jackson Laboratories) ages 2 to 5 months (10 to 65 g)] of a similar age were randomized according to body weight into 4 groups of 10 mice. The mice were housed 5 per cage and are maintained on normal rodent chow with water ad libitum. Mice received test compound daily by gavage (suspended in 0.5 ml of 0.5% methyl cellulose); dissolved in the drinking water; or admixed in the diet. The dose of compounds given ranges from 2.5 to 200 mg/kg body weight/day. The dose is calculated based on the fed weekly body weight and is expressed as active moiety. The positive control, ciglitazone (5-(4-(l-methylcyclohexylmethoxy)benzyl)-2,4-dione, see Chang, A., Wyse, B., Gilchrist, B., Peterson, T. and Diani, A. Diabetes 32: 830-838, 1983.) was given at a dose of 100 mg/kg/day, which produces a significant lowering in plasma glucose. Control mice received vehicle only.
On the morning of Day 4, 7 or 14 two drops of blood (approximetly 50 ul) were collected into sodium fluoride containing tubes either from the tail vein or after decapitation. For those studies in which the compound was administered daily by gavage the blood samples were collected two hours after compound administration. The plasma was isolated by centrifugation and the concentration of glucose is measured enzymatically on an Abbott V.P. Analyzer.
For each mouse, the percentage change in plasma glucose on Day 4, 7 or 14 is calculated relative to the mean plasma glucose of the vehicle treated mice. Analysis of variance followed by Dunett's Comparison Test (one-tailed) are used to estimate the significant difference between the plasma glucose values from the control group and the individual compound treated groups ( CMS SAS Release 5.18).
The results shown in the table below shows that the compounds of this invention are antihyperglycemic agents as they lower blood glucose levels in diabetic mice.
a Statistically (p < 0.05) significant. Based on the results obtained in the standard pharmacological test procedures, representative compounds of this invention have been shown to inhibit PTPase activity and lower blood glucose levels in diabetic mice, and are therefore useful in treating metabolic disorders related to insulin resistance or hyperglycemia, typically associated with obesity or glucose intolerance. More particularly, the compounds of this invention useful in the treatment or inhibition of type II diabetes, and in modulating glucose levels in disorders such as type I diabetes. As used herein, the term modulating means maintaining glucose levels within clinically normal ranges.
Effective administration of these compounds may be given at a daily dosage of from about 1 mg kg to about 250 mg/kg, and may given in a single dose or in two or more divided doses. Such doses may be administered in any manner useful in directing the active compounds herein to the recipient's bloodstream, including orally, via implants, parenterally (including intravenous, intraperitoneal and subcutaneous injections), rectally, vaginally, and transdermally. For the purposes of this disclosure, transdermal administrations are understood to include all administrations across the surface of the body and the inner linings of bodily passages including epithelial and mucosal tissues. Such administrations may be carried out using the present compounds, or pharmaceutically acceptable salts thereof, in lotions, creams, foams, patches, suspensions, solutions, and suppositories (rectal and vaginal).
Oral formulations containing the active compounds of this invention may comprise any conventionally used oral forms, including tablets, capsules, buccal forms, troches, lozenges and oral liquids, suspensions or solutions. Capsules may contain mixtures of the active compound(s) with inert fillers and/or diluents such as the pharmaceutically acceptable starches (e.g. corn, potato or tapioca starch), sugars, artificial sweetening agents, powdered celluloses, such as crystalline and microcrystalline celluloses, flours, gelatins, gums, etc. Useful tablet formulations may be made by conventional compression, wet granulation or dry granulation methods and utilize pharmaceutically acceptable diluents, binding agents, lubricants, disintegrants, suspending or stabilizing agents, including, but not limited to, magnesium stearate, stearic acid, talc, sodium lauryl sulfate, microcrystalline cellulose, carboxymethyl- cellulose calcium, polyvinylpyrrolidone, gelatin, alginic acid, acacia gum, xanthan gum, sodium citrate, complex silicates, calcium carbonate, glycine, dextrin, sucrose, sorbitol, dicalcium phosphate, calcium sulfate, lactose, kaolin, mannitol, sodium chloride, talc, dry starches and powdered sugar. Oral formulations herein may utilize standard delay or time release formulations to alter the absorption of the active compound(s). Suppository formulations may be made from traditional materials, including cocoa butter, with or without the addition of waxes to alter the suppository's melting point, and glycerin. Water soluble suppository bases, such as polyethylene glycols of various molecular weights, may also be used.
It is understood that the dosage, regimen and mode of administration of these compounds will vary according to the malady and the individual being treated and will be subject to the judgment of the medical practitioner involved. It is preferred that the administration of one or more of the compounds herein begin at a low dose and be increased until the desired effects are achieved.
The following procedures describe the preparation of representative examples of this invention.
Example 1
4-(4,-Methoxy-biphenyl-4-yl -5-methyl-2-(4-trifluoromethyl-phenylVoxazole
Step a) 1 -(4-bromo-phenyiypropanone oxime
Sodium acetate (80.0g, 976 mmol) was added into a mixture of l(4-bromo- phenyl)-propanone (52.0 g, 244 mmol), hydroxylamine hydrochloride (50.8 g, 732.3 mmol), ethyl alcohol (500 mL) and water (100 mL). The reaction mixture was stirred at 60 ° C for 1 hour, poured into water, and extracted with ethyl ether. The organic extracts were dried over MgSO4. Evaporation and crystallization from ethyl ether / hexanes gave a white solid (49.6 g, 89% yield); MS m/e 227(M+); Analysis for C9H10BrNO: Calc'd: C, 47.39; H, 4.42; N, 6.14 Found: C, 47.42; H, 4.37; N, 5.99
Step b) 4-(4-Bromo-phenyl)-5-methyl-2-(4-trifluoromethyl-phenyl)-oxazole
Pyridine (3.55 mL, 43.86 mmol) was added into a mixture of l-(4-bromo- phenyl)-propanone oxime (lO.Og, 43.86 mmol) and toluene (20 mL). The reaction mixture was stirred for 30 minutes, and then 4-trifluoromethyl-phenyl acetyl chloride (16.27 mL, 109.6 mmol) was added dropwise. The new mixture was stirred at 100 °C for 24 hours, and then w as poured into water and extracted with ethyl acetate. The organic extracts were dried over MgSO4. Evaporation and purification by flash chromatography on silica gel (hexanes/EtAOc 40:1) gave a white solid (7.3 g, 43% yield): mp 82.84 °C; MS m e 381 (M+); Analysis for: C17HπBrF3NO Calc'd: C, 53.43; H, 2.90; N, 3.67 Found: C, 53.47; H, 2.62; N, 3.43
Step c) 4-(4,-methoxy-biphenyl-4-ylV5-methyl-2-(4-trifluoromethyl-phenyl)-oxazole 4-Methoxy-benzeneboronic acid (1.44 g, 7.19 mmol) in ethyl alcohol (5 mL) was added into a mixture of 4-(4-bromo-phenyl)-5-methyl-2-(4-trifluoromethyl- phenyl)-oxazole (2.5 g, 6.54mmol), sodium carbonate (2N, 6.5 mL), tetrakis- (triphenylphosphine)palladium(O) (0.23 g, 0.196 mmol), and toluene (200 mL). The reaction mixture was refluxed for 12 hours, cooled to room temperature, and treated with hydrogen peroxide (30%, 5 mL) for 1 hour. Then, the mixture was poured into water and extracted with ethyl acetate. The organic extracts were dried over MgSO Evaporation and crystallization from hexanes/ethyl ether gave a white solid (2.2 g, 82% yield): mp 167-168 °C; MS m/e 409 (M+); Analysis for: C24H18F3NO2 Calc'd: C, 70.41; H, 4.43; N, 3.42 Found: C, 70.14; H, 4.32; N, 3.30
Example 2
4-(4'-Methoxy-biphenyl-3-yD-5-methyl-2-(4-trifluoromethyl-phenylVoxazole
The title compound was prepared from 4-(4-bromo-phenyl)-5-methyl-2-(4- trifluoromethyl-phenyl)-oxazole, and 4-methoxy-benzeneboronic acid in substantially the same manner, as described in Example 1 step c, and was obtained as a white solid, mp 93-94 °C; MS m/e 409 (M+);
Analysis for: C24H18F3NO2 Calc'd: C, 70.41; H, 4.43; N, 3.42 Found: C, 70.25; H,
4.33; N, 3.34
Example 3
4,-r5-Methyl-2-(4-trifluoromethyl-phenylVoxazol-4-yll-biphenyl-4-ol
Boron tribromide (1.0 M, 3.91 mL, 3.91 mmol) was added dropwise into a cold (-78 ° mixture of 4-(4'-methoxy-biphenyl-4-yl)-5-methyl-2-(4-trifluoromethyl- phenyl)-oxazole (1.6 g, 3.91 mmol), and dichloromethane (20 mL). The reaction mixture was allowed to come gradually to room temperature and stirred for 10 hours.
Then, the mixture was cooled to 0 °C and methyl alcohol (5 mL) was added dropwise.
After stirring for 10 minutes the mixture was poured into water and extracted with ethyl ether. The organic extracts were dried over MgSO Evaporation and crystallization from ethyl ether/hexanes gave an off-white solid (1.4 g, 90% yield): mp 189-191; MS m/e 396 (M+H)+;
Analysis for: C23H16F3NO2 x 0.3 H2O Calc'd: C, 68.92; H, 4.17; N, 3.50 Found: C, 68.97; H, 4.23; N, 3.33
Example 4 3'-r5-Methyl-2-(4-trifluoromethyl-phenylVoxazol-4-yl]-biphenyl-4-ol
The title compound was prepared from 4-(4'-methoxy-biphenyl-3-yl)-5-methyl- 2-(4-trifluoromethyl-phenyl)-oxazole, in substantially the same manner, as described in Example 3, and was obtained as a white solid, mp 133-135 °C; MS m/e 395 (M+);
Analysis for: C23H16F3NO2 x 0.3 H2O Calc'd: C, 68.92; H, 4.17; N, 3.50 Found: C, 68.98; H, 3.83; N, 3.47
Example 5 f4'-r5-methyl-2-(4-trifluoromethyl-phenylVoxazol-4-yll-biphenyl-4-yloxy}-acetic acid
Sodium hydride (0.05g, 1.26 mmol) was added into a mixture of 4'-[5-methyl-
2-(4-trifluoromethyl-phenyl)-oxazol-4-yl]-biphenyl-4-ol (0.5 g, 1.26 mmol), and N,N- dimethylformamide (5.0 mL). The reaction mixture was stirred at room temperature for
1 hour. Methyl bromoacetate (0.18 mL, 1.89 mmol) was added dropwise into the mixture. After stirrng for 30 minutes, the mixture was poured into water and extracted with ethyl acetate. The organic extracts were dried over MgSO Evaporation gave a yellow oil (0.61 g). This residue was taken in methyl alcohol (20 mL) and tetrahydrofuran (20 mL), and treated with NaOH (2.5 N, 5.0 mL) for 30 minutes. The new reaction mixture was then poured into water, acidified with HCI (2 N), and extracted with ethyl ether. The organic extracts were dried over MgSO4. Evaporation and crystallization form hexanes / ethyl ether gave an off-white solid (0.42 g, 73 % yield): mp 209-211; MS m/e 454 (M+H)+;
Analysis for: C25H18F3NO4 Calc'd: C, 66.23; H, 4.00; N, 3.09 Found: C, 65.97; H, 3.93; N, 3.04
Example 6
( 3 ' - r5-Methyl-2-(4-trifluoromethyl-phenyl -oxazol-4-yl1 -bipheny 1-4-yloxy 1 -acetic acid The title compound was prepared from 3'-[5-methyl-2-(4-trifluoromethyl- phenyl)-oxazol-4-yl]-biphenyl-4-ol, in substantially the same manner, as described in Example 6, and was obtained as a light yellow solid, mp 178-179 °C; MS m/e 453
(M+);
Analysis for: C25H18F3NO4 x 0.3 H2O Calc'd: C, 65.44; H, 3.99; N, 3.05 Found: C,
65.50; H, 3.93; N, 2.92
Example 7
2- ( 4' - r5-Methyl-2-(4-trifluoromethyl-phenylVoxazol-4-yl]-biphenyl-4-yloxy } -3- phenyl-propionic acid
Diisopropyl azodicarboxylate (0.42 mL, 2.52 mmol) in benzene (10 mL) was added dropwise into a cold (0 °C) mixture of 4'-[5-methyl-2-(4-trifluoromethyl- phenyl)-oxazol-4-yl]-biphenyl-4-ol (0.5 g, 1.26 mmol), 3-phenyllactic acid methyl ester (0.45 g, 2.52 mmol), triphenylphosphine (0.66 g, 2.52 mmol), and benzene (20 mL). The reaction mixture was stirred at room temperature for 30 minutes, poured into water, and extracted with ethyl ether. The organic extracts were dried over MgSO4. Evaporation gave a yellow oil (0.6 g). This residue was taken in methyl alcohol (15 mL) and tetrahydrofuran (15 mL) and treated with sodium hydroxide (2 N, 3.0 mL).
The reaction mixture was stirred for 30 minutes, poured into water, acidified with HCI
(2 N), and extracted with ethyl ether. The organic extracts were dried over MgSO
Evaporation and crystallization from ethyl ether/hexanes gave a white solid (0.38 g, 55% yield): mp 183- 184; MS m/e 544 (M+H)+;
Analysis for: C32H24F3NO4 Calc'd: C, 70.71; H, 4.45; N, 2.58 Found: C, 70.50; H,
4.32; N, 2.53
Example 8 2- { 3 ' -r5-Methyl-2-(4-trifluoromethyl-phenyl -oxazol-4-yn-biphenyl-4-yloxy } -3- phenyl-propionic acid
The title compound was prepared from 3'-[5-methyl-2-(4-trifluoromethyl- phenyl)-oxazol-4-yl]-biphenyl-4-ol, in substantially the same manner, as described in
Example 7, and was obtained as a white solid, mp 148-149 °C; MS m/e 543 (M+); Analysis for: C32H24F3NO4 Calc'd: C, 70.71; H, 4.45; N, 2.58 Found: C, 70.72; H ,
4.28; N, 2.50 Example 9
3.5-Dibromo-4'-r5-methyl-2-(4-trifluoromethyl-phenyl)-oxazol-4-yll-biphenyl-4-ol
Bromine (0.73 mL, 14.18 mmol) in acetic acid (50 mL) was added dropwise over a 30 minutes period into a cold (5 °C) mixture of 4'-(2-benzyl-benzo[b]thiophen- 3-yl)-biphenyl-4-ol (2.8 g, 7.09 mmol), potassium acetate (6.95 g, 70.9 mmol), and acetic acid (200 mL). After the addition, the mixture was poured into water. The precipitated solid was filtered, washed with water and dried to afford a white solid (2.1 g; 61% yield): mp 79-81 °C MS m/e 551 (M+);
Analysis for: C23H14Br2F3NO2 Calc'd: C, 49.94; H, 2.55; N, 2.53 Found: C, 49.78; H, 2.46; N, 2.49
Example 10
(3.5-Dibromo-4,-r5-methyl-2-(4-trifluoromethyl-phenyl)-oxazol-4-yll-biphenyl-4- yloxyl -acetic acid The title compound was prepared from 3,5-dibromo-4'-[5-methyl-2-(4- trifluoromethyl-phenyl)-oxazol-4-yl]-biphenyl-4-ol, and methyl bromoacetate in substantially the same manner, as described in Example 5, and was obtained as an off- white solid, mp 165-166 °C; MS m/e 609 (M+); Analysis for: C25H16Br2F3NO4 Calc'd: C, 49.13; H, 2.64; N, 2.29 Found: C, 49.24; H, 2.58; N, 2.16
Example 11
2-{3.5-Dibromo-4'-15-methyl-2-(4-trifluoromethyl-phenylVoxazol-4-yll-biphenyl-4- yloxyl-3-phenyl-propionic acid methyl ester The title compound was prepared from 3,5-dibromo-4'-[5-methyl-2-(4- trifluoromethyl-phenyl)-oxazol-4-yl]-biphenyl-4-ol, and 3-phenyllactic acid methyl ester in substantially the same manner, as described in Example 7, and was obtained as a white solid, mp 70-72 °C; MS m/e 713 (M+);
Analysis for: C33H24Br2F3NO4 Calc'd: C, 55.41; H, 3.38; N, 1.96 Found: C, 55.01; H, 3.21; N, 1.99
Example 12
2- 13.5-Dibromo-4' -[5-methyl-2-(4-trifluoromethyl-phenylVoxazol-4-yll-biphenyl-4- yloxyl-3-phenyl-propionic acid The title compound was prepared from 2-{3,5-dibromo-4'-[5-methyl-2-(4- trifluoromethyl-phenyl)-oxazol-4-yl]-biphenyl-4-yloxy } -3-phenyl-propionic acid methyl ester in substantially the same manner, as described in Example 7, and was obtained as a white solid, mp 241-243 °C; MS m/e 699 (M+);
Analysis for: C32H22Br2F3NO4 Calc'd: C, 54.80; H, 3.16; N, 2.00 Found: C, 54.54;
H, 3.03; N, 2.00
Example 13
2-(4,-[5-methyl-2-(4-trifluoromethyl-phenyl)-oxazol-4-yll-biphenyl-4-ylmethyl}-
T 1.2.4]oxadiazolidine-3.5-dione
Step a) 4'-r5-Methyl-2-(4-trifluoromethyl-phenylVoxazol-4-yll-biphenyl-4- carbaldehyde
This compound was prepared from 4-(4-bromo-phenyl)-5-methyl-2-(4- trifluoromethyl-phenyl)-oxazole, and 4-formylbenzeneboronic acid in substantially the same manner, as described in Example 1 step c, and was obtained as an off-white solid;
MS m/e 407 (M+); Analysis for: C24H16F3NO2 Calc'd: C, 70.76; H, 3.96; N, 3.44 Found: C, 70.83; H,
3.70; N, 3.42
Step b) 4'-r5-Methyl-2-(4-trifluoromethyl-phenyl -oxazol-4-yll-biphenyl-4- carbaldehyde oxime This compound was prepared from 4'-[5-methyl-2-(4-trifluoromethyl-phenyl)- oxazol-4-yl]-biphenyl-4-carbaldehyde, and hydroxylamine in substantially the same manner, as described in Example 1 step a, and was obtained as an off-white solid; MS m/e 422 (M+);
Analysis for: C24H17F3N2O2 Calc'd: C, 68.24; H, 4.06; N, 6.63 Found: C, 68.10; H, 3.82; N, 6.45
Step c) N-{4'-r5-Methyl-2-(4-trifluoromethyl-phenyl)-oxazol-4-yll-biphenyl-4- ylmethyl 1 -hydroxylamine
Hydrochloric acid (4 N, in dioxane, 10 mL) was added dropwise into a mixture of 4'- [5-methyl-2-(4-trifluoromethyl-phenyl)-oxazol-4-yl]-biphenyl-4-carbaldehyde oxime
(1.5 g, 3.56 mmol), sodium cyanoborohydride (1.1 g, 17.81 mmol), methyl alcohol (100 mL), and tetrahydrofuran (100 mL). The reaction mixture was stirred for 1 hour poured into water, basified with sodium hydroxide (2 N), and extracted with ethyl acetate. The organic extracts were dried over MgSO4. Evaporation and purification by flash chromatography on silica gel (EtOAc/MeOH 20:1) gave an off-white solid (1.21 g, 80% yield); MS m/e 424 (M+);
Analysis for: C24H19F3N2O2 x H2O Calc'd: C, 67.06; H, 4.60; N, 6.52 Found: C,
67.10; H, 4.34; N, 6.69
Step d) 2-(4,-f5-Methyl-2-(4-trifluoromethyl-phenylVoxazol-4-yl]-biphenyl-4- ylmethyl 1 -\ 1.2.41oxadiazolidine-3.5-dione
N-(Chlorocarbonyl)isocyanate (0.2 mL, 2.6 mmol) was added dropwise into a cold (-5 °Q mixture of N-{4'-[5-methyl-2-(4-trifluoromethyl-phenyl)-oxazol-4-yl]- biphenyl-4-ylmethyl} -hydroxylamine (1.1, 2.6 mmol), and tetrahydrofuran (20.0 mL).
The reaction mixture was stirred for 30 minutes, poured into water, acidified with HCI
(2 N), and extracted with ethyl acetate. The organic extracts were dried over MgSO4.
Evaporation and purification by flash chromatography on acidic silica gel
(hexanes/EtOAc 2:1) gave a white solid (0.68 g, 53% yield): mp 196-198; MS m/e 493 (M+);
Analysis for: C26H18F3N3O4 Calc'd: C, 63.29; H, 3.68; N, 8.52 Found: C, 62.95; H,
3.51; N, 8.40
Example 14 2- ( 4' - r5-Methyl-2-(4-trifluoromethyl-phenyl Voxazol-4-yll-biphenyl-3-ylmethyl 1 - π.2.41oxadiazolidine-3.5-dione
This compound was prepared from 3-(4-bromo-phenyl)-5-methyl-2-(4- trifluoromethyl-phenyl)-oxazole in substantially the same manner, as described in
Example 1 steps a-d, and was obtained as a white solid, mp 216-218; MS m/e 493 (M+);
Analysis for: C26H18F3N3O4 Calc'd: C, 63.29; H, 3.68; N, 8.52 Found: C, 63.23; H,
3.43; N, 8.48
Example 15 5-(4,-r5-Methyl-2-(4-trifluoromethyl-phenyl)-oxazol-4-yll-biphenyl-4-yloxymethyll- lH-tetrazole
Sodium hydride (O.lg, 2.52 mmol) was added into a mixture of 4'-[5-methyl-
2-(4-trifluoromethyl-phenyl)-oxazol-4-yl]-biphenyl-4-ol (1.0 g, 2.52 mmol), and N,N- dimethylformamide (5.0 mL). The reaction mixture was stirred at room temperature for 1 hour. Methyl bromoacetonitrile (0.17 mL, 2.52 mmol) was added dropwise into the mixture. After stirring for 30 minutes, the mixture was poured into water and extracted with ethyl acetate. The organic extracts were dried over MgSO Evaporation gave a yellow oil (1.1 g). This residue was taken in N,N-dimethylformamide (20 mL), and treated with ammonium chloride (0.67 g, 12.6 mmol), and sodium azide (0.82 g, 12.6 mmol) at 120 °C for 10 hours. The mixture was then poured into water, acidified with HCI (2 N), and extracted with ethyl ether. The organic extracts were dried over MgSO Evaporation and crystallization form hexanes / ethyl ether gave a white solid (0.49 g, 41 % yield): mp 226-227; MS m/e 477 (M+);
Analysis for: C25H18F3N5O2 Calc'd: C, 62.89; H, 3.80; N, 14.67 Found: C, 62.54; H, 3.63; N, 14.76
Example 16
{ l-Bromo-6-[5-methyl-2-(4-trifluoromethyl-phenyD-oxazol-4-yll-naphthalen-2- yloxy I -acetic acid
Step a) 4'-(6-Methoxy-naphthalen-2-yl")-5-methyl-2-(4-trifluoromethyl-phenylV oxazole
This compound was prepared from l-(6-methoxy-naphthalen-2-yl)propanone oxime, and 4-trifluoromethyl-phenyl acetyl chloride in substantially the same manner, as described in Example 1 steps b, and was obtained as a white solid, mp 138-139; MS m/e 383 (M+); Analysis for: C22H19F3NO2 Calc'd: C, 68.93; H, 4.21; N, 3.65 Found: C, 68.83; H,
4.25; N, 3.70
Step b) 6-r5-Methyl-2-(4-trifluoromethyl-phenylVoxazol-4-yll-naphthalen-2-ol
This compound was prepared from 4'-(6-methoxy-naphthalen-2-yl)-5-methyl- 2-(4-trifluoromethyl-phenyl)-oxazole and boron tribromide in substantially the same manner, as described in Example 3, and was obtained as a white solid, mp 188-191; MS m/e 370 (M+H)+;
Analysis for: C21H14F3NO2 Calc'd: C, 68.29; H, 3.82; N, 3.79 Found: C, 67.81; H, 3.76; N, 3.66
Step c) l-Bromo-6-15-ethyl-2-(4-trifluoromethyl-phenyl)-oxazol-4-yn-naphthalen-2-ol This compound was prepared from 4'-(6-hydroxy-naphthalen-2-yl)-5-methyl-2- (4-trifluoromethyl-phenyl)-oxazole and bromine in substantially the same manner, as described in Example 9, and was obtained as an off-white solid; MS m/e 447 (M+); Analysis for: C21H13BrF3NO2 Calc'd: C, 56.27; H, 2.92; N, 3.12 Found: C, 56.20; H, 2.66; N, 3.15
Step d) ( l-Bromo-6-r5-methyl-2-(4-trifluoromethyl-phenylVoxazol-4-yn-naphthalen- 2-yloxy I -acetic acid
This compound was prepared from 4'-(5-bromo-6-hydroxy-naphthalen-2-yl)-5- methyl-2-(4-trifluoromethyl-phenyl)-oxazole and methyl bromoacetate in substantially the same manner, as described in Example 5, and was obtained as white solid, mp 212- 214 °C; MS m/e 506 (M+H)+; Analysis for: C23H15BrF3NO4 Calc'd: C, 54.57; H, 2.99; N, 2.77 Found: C, 54.17; H, 2.69; N, 2.76
Example 17
2- { 1 -Bromo-6- [5-methyl-2-(4-trifluoromethyl-phenyl Voxazol-4-yl]-naphthalen-2- yloxyl-3-phenyl-propionic acid
This compound was prepared from 4'-(5-bromo-6-hydroxy-naphthalen-2-yl)-5- methyl-2-(4-trifluoromethyl-phenyl)-oxazole and methyl bromoacetate in substantially the same manner, as described in Example 7, and was obtained as an off-white solid, mp 195-197 °C; MS m/e 596 (M+H)+; Analysis for: C30H21BrF3NO4 Calc'd: C, 60.42; H, 3.55; N, 2.35 Found: C, 60.31; H,
3.35; N, 2.42

Claims

WHAT IS CLAIMED IS:
A compound of formula I having the structure
wherein
R1 is alkyl of 1-6 carbon atoms, cycloalkyl of 3-8 carbon atoms, thienyl, furyl, pyridyl,
R2 is hydrogen, alkyl of 1-6 carbon atoms, or aryl of 6 to 10 carbon atoms;
R3 and R4 are independently halogen, hydrogen, alkyl of 1-12 carbon atoms , aryl of 6 to 10 carbon atoms; halogen, trifluoromethylof 1-6 carbon atoms, alkoxyaryl of 7-14 carbon atoms; nitro, amino, carboalkoxy, carbamide, carbamate, urea, alkylsulfoamide, -NR7(CH2)mCO2H, arylsulfoamide, cycloalkyl of 3-8 carbon atoms, or heterocycle of 5 to 7 atom rings containing from 1 to 3 heteroatoms selected from oxygen, nitrogen, or sulfur;
R5 is hydrogen, alkyl of 1-6 carbon atoms, -CH(R8)R9, -C(CH2)nCO2R10,
-C(CH3)2CO2R10, -CH(R8)(CH2)nCO2R10, -CH(R8)C6H4CO2Rl0, or -CH2- tetrazole;
R6 is hydrogen, alkyl of 1-6 carbon atoms, halogen, alkyoxy of 1-6 carbon atoms, trifluoroalkyl of 1-6 carbon atoms or trifluoroalkoxy of 1-6 carbon atoms; R7 is hydrogen or alkyl of 1 to 6 carbon atoms; R8 is hydrogen, alkyl of 1-6 carbon atoms, aryl of 6-10 carbon atoms, arylalkyl of 7-15 carbon atoms, cycloalkyl of 3-8 carbon atoms, phthalic acid,
R9 is CO2R12, CONHR12, tetrazole, PO3R12; R10is hydrogen, alkyl of 1-6 carbon atoms, aryl of 6-12 carbon atoms, aralkyl of 7-15 carbon atoms; R11 is alkylene of 1 to 3 carbon atoms;
R12is hydrogen, alkyl of 1-6 carbon atoms, aryl of 6-12 carbon atoms, aralkyl of 7-15 carbon atoms; X is O, or S; Y is O, N, or S; Z is C, or N; Q is O, N, or S; m = 1-3; n = l-6, or a pharmaceutically acceptable salt thereof.
2. The compound according to claim 1, wherein X is oxygen, or a pharmaceutically acceptable salt thereof.
3. The compound according to claim 2, wherein
R1 is phenyl substituted with R6;
R2 is alkyl of 1-6 carbon atoms; and
R3 and R4 are each, independently, hydrogen or halogen; or a pharmaceutically acceptable salt thereof.
4. The compound of claim 1 which is 4-(4'-methoxy-biphenyl-4-yl)-5-methyl-2- (4-tτifluoromethyl-phenyl)-oxazole or a pharmaceutically acceptable salt thereof.
5. The compound of claim 1 which is 4-(4'-methoxy-biphenyl-3-yl)-5-methy 1-2- (4-trifluoromethyl-phenyl)-oxazole or a pharmaceutically acceptable salt thereof.
6. The compound of claim 1 which is 4'-[5-methyl-2-(4-trifluoromethyl-phenyl)- oxazole-4-yl]-biphenyl-4-ol or a pharmaceutically acceptable salt thereof.
7. The compound of claim 1 which is 3'-[5-methyl-2-(4-trifluoromethyl-phenyl)- oxazol-4-yl]-biphenyl-4-ol or a pharmaceutically acceptable salt thereof.
8. The compound of claim 1 which is {4'-[5-methyl-2-(4-trifluoromethyl-phenyl)- oxazol-4-yl]-biphenyl-4-yloxy } -acetic acid or a pharmaceutically acceptable salt thereof.
9. The compound of claim 1 which is {3'-[5-methyl-2-(4-trifluoromethyl-phenyl)- oxazol-4-yl]-biphenyl-4-yloxy) -acetic acid or a pharmaceutically acceptable salt thereof.
10. The compound of claim 1 which is 2-{4'-[5-methyl-2-(4-trifluoromethyl- phenyl)-oxazol-4-yl]-biphenyl-4-yloxy}-3-phenyl-propionic acid or a pharmaceutically acceptable salt thereof.
1 1. The compound of claim 1 which is 2-{3'-[5-methyl-2-(4-trifluoromethyl- phenyl)-oxazol-4-yl]-biphenyl-4-yloxy}-3-phenyl-propionic acid or a pharmaceutically acceptable salt thereof.
12. The compound of claim 1 which is 3,5-dibromo-4'-[5-mefhyl-2-(4- trifluoromethyl-phenyl)-oxazol-4-yl]-biphenyl-4-ol or a pharmaceutically acceptable salt thereof.
13. The compound of claim 1 which is {3,5-dibromo-4'-[5-methyl-2-(4-trifluoro- methyl-phenyl)-oxazol-4-yl]-biphenyl-4-yloxy} -acetic acid or a pharmaceutically acceptable salt thereof.
14. The compound of claim 1 which is 2-{3,5-dibromo-4'-[5-methyl-2-(4-trifluoro- methyl-phenyl)-oxazol-4-yl]-biphenyl-4-yloxy}-3-phenyl-propionic acid methyl ester or a pharmaceutically acceptable salt thereof.
15. The compound of claim 1 which is 2-{3,5-dibromo-4'-[5-methyl-2-(4- trifluoromethyl-phenyl)-oxazol-4-yl]-biphenyl-4-yloxy}-3-phenyl-propionic acid or a pharmaceutically acceptable salt thereof.
16. The compound of claim 1 which is 2-{4'-[5-methyl-2-(4-trifluoromethyl- phenyl)-oxazol-4-yl]-biphenyl-4-ylmethyl}-[l,2,4]oxadiazolidine-3,5-dione or a pharmaceutically acceptable salt thereof.
17. The compound of claim 1 which is 2-{4'-[5-methyl-2-(4-trifluoromethyl- phenyl)-oxazol-4-yl]-biphenyl-3-ylmethyl}-[l,2,4]oxadiazolidine-3,5-dione or a pharmaceutically acceptable salt thereof.
18. The compound of claim 1 which is 5-{4'-[5-methyl-2-(4-trifluoromethyl- phenyl)-oxazol-4-yl]-biphenyl-4-yloxymethyl}-lH-tetrazole or a pharmaceutically acceptable salt thereof.
19. A method of treating metabolic disorders mediated by insulin resistance or hyperglycemia in a mammal in need thereof which comprises administering to said mammal, a compound of formula I having the structure
wherein
R1 is alkyl of 1-6 carbon atoms, cycloalkyl of 3-8 carbon atoms, thienyl, furyl, pyridyl,
R2 is hydrogen, alkyl of 1-6 carbon atoms, or aryl of 6 to 10 carbon atoms; R3 and R4 are independently halogen, hydrogen, alkyl of 1-12 carbon atoms , aryl of 6 to 10 carbon atoms; halogen, trifluoromethylof 1-6 carbon atoms, alkoxyaryl of 7-14 carbon atoms; nitro, amino, carboalkoxy, carbamide, carbamate, urea, alkylsulfoamide, -NR7(CH )mCO2H, arylsulfoamide, cycloalkyl of 3-8 carbon atoms, or heterocycle of 5 to 7 atom rings containing from 1 to 3 heteroatoms selected from oxygen, nitrogen, or sulfur;
R5 is hydrogen, alkyl of 1-6 carbon atoms, -CH(R8)R9, -C(CH2)nCO2R10,
-C(CH3)2CO2R10, -CH(R8)(CH2)nCO2R10, -CH(R8)C6H4CO2R10, or -CH2- tetrazole; R6 is hydrogen, alkyl of 1-6 carbon atoms, halogen, alkyoxy of 1-6 carbon atoms, trifluoroalkyl of 1-6 carbon atoms or trifluoroalkoxy of 1-6 carbon atoms;
R7 is hydrogen or alkyl of 1 to 6 carbon atoms;
R8 is hydrogen, alkyl of 1-6 carbon atoms, aryl of 6-10 carbon atoms, arylalkyl of 7-15 carbon atoms, cycloalkyl of 3-8 carbon atoms, phthalic acid,
R9 is CO2R12, CONHR12, tetrazole, PO3R12;
R10is hydrogen, alkyl of 1-6 carbon atoms, aryl of 6-12 carbon atoms, aralkyl of 7-15 carbon atoms;
R1 ] is alkylene of 1 to 3 carbon atoms; R12 is hydrogen, alkyl of 1 -6 carbon atoms, aryl of 6- 12 carbon atoms, aralkyl of 7- 15 carbon atoms;
X is O, or S;
Y is O, N, or S;
Z is C, or N; Q is O, N, or S; m = 1-3; n = 1-6, or a pharmaceutically acceptable salt thereof.
20. A method of treating or inhibiting type II diabetes in a mammal in need thereof which comprises administering to said mammal, a compound of formula I having the structure
wherein
R1 is alkyl of 1-6 carbon atoms, cycloalkyl of 3-8 carbon atoms, thienyl, furyl, pyridyl,
R2 is hydrogen, alkyl of 1-6 carbon atoms, or aryl of 6 to 10 carbon atoms;
R3 and R4 are independently halogen, hydrogen, alkyl of 1-12 carbon atoms , aryl of 6 to 10 carbon atoms; halogen, trifluoromethylof 1-6 carbon atoms, alkoxyaryl of 7-14 carbon atoms; nitro, amino, carboalkoxy, carbamide, carbamate, urea, alkylsulfoamide, -NR7(CH2)mCO2H, arylsulfoamide, cycloalkyl of 3-8 carbon atoms, or heterocycle of 5 to 7 atom rings containing from 1 to 3 heteroatoms selected from oxygen, nitrogen, or sulfur;
R5 is hydrogen, alkyl of 1-6 carbon atoms, -CH(R8)R9, -C(CH2)nCO2R10,
-C(CH3)2CO2R10, -CH(R8)(CH2)nCO2R10, -CH(R8)C6H4CO2Rl0, 0r -CH2- tetrazole;
R6 is hydrogen, alkyl of 1-6 carbon atoms, halogen, alkyoxy of 1-6 carbon atoms, trifluoroalkyl of 1-6 carbon atoms or trifluoroalkoxy of 1-6 carbon atoms; R7 is hydrogen or alkyl of 1 to 6 carbon atoms;
R8 is hydrogen, alkyl of 1-6 carbon atoms, aryl of 6-10 carbon atoms, arylalkyl of 7-15 carbon atoms, cycloalkyl of 3-8 carbon atoms, phthalic acid,
R9 is CO2R12, CONHR12, tetrazole, PO3R12;
R10is hydrogen, alkyl of 1-6 carbon atoms, aryl of 6-12 carbon atoms, aralkyl of 7-15 carbon atoms;
R11 is alkylene of 1 to 3 carbon atoms;
R12is hydrogen, alkyl of 1-6 carbon atoms, aryl of 6-12 carbon atoms, aralkyl of 7-15 carbon atoms;
X is O, or S;
Y is O, N, or S;
Z is C, or N;
Q is O, N, or S; m = l-3; n = 1-6, or a pharmaceutically acceptable salt thereof.
21. A method of modulating glucose levels in a mammal in need thereof which comprises administering to said mammal, a compound of formula I having the structure
wherein
R1 is alkyl of 1-6 carbon atoms, cycloalkyl of 3-8 carbon atoms, thienyl, furyl, pyridyl,
R2 is hydrogen, alkyl of 1-6 carbon atoms, or aryl of 6 to 10 carbon atoms;
R3 and R4 are independently halogen, hydrogen, alkyl of 1-12 carbon atoms , aryl of 6 to 10 carbon atoms; halogen, trifluoromethylof 1-6 carbon atoms, alkoxyaryl of 7-14 carbon atoms; nitro, amino, carboalkoxy, carbamide, carbamate, urea, alkylsulfoamide, -NR7(CH2)mCO2H, arylsulfoamide, cycloalkyl of 3-8 carbon atoms, or heterocycle of 5 to 7 atom rings containing from 1 to 3 heteroatoms selected from oxygen, nitrogen, or sulfur;
R5 is hydrogen, alkyl of 1-6 carbon atoms, -CH(R8)R9, -C(CH2)nCO2R10,
-C(CH3)2CO2R10, -CH(R8)(CH2)nCO2R10, -CH(R8)C6H4CO2R10, or -CH2- tetrazole; R6 is hydrogen, alkyl of 1-6 carbon atoms, halogen, alkyoxy of 1-6 carbon atoms, trifluoroalkyl of 1-6 carbon atoms or trifluoroalkoxy of 1-6 carbon atoms;
R7 is hydrogen or alkyl of 1 to 6 carbon atoms;
R8 is hydrogen, alkyl of 1-6 carbon atoms, aryl of 6-10 carbon atoms, arylalkyl of 7-15 carbon atoms, cycloalkyl of 3-8 carbon atoms, phthalic acid,
R9 is CO2R12, CONHR12, tetrazole, PO3R12;
R10is hydrogen, alkyl of 1-6 carbon atoms, aryl of 6-12 carbon atoms, aralkyl of 7-15 carbon atoms; R11 is alkylene of 1 to 3 carbon atoms; R12is hydrogen, alkyl of 1-6 carbon atoms, aryl of 6-12 carbon atoms, aralkyl of 7-15 carbon atoms; X is O, or S; Y is O, N, or S;
Z is C, or N;
Q is O, N, or S; m = 1-3; n = 1-6, or a pharmaceutically acceptable salt thereof.
22. A pharmaceutical composition which comprises a compound of formula I having the structure
wherein
R1 is alkyl of 1-6 carbon atoms, cycloalkyl of 3-8 carbon atoms, thienyl, furyl, pyridyl,
R2 is hydrogen, alkyl of 1-6 carbon atoms, or aryl of 6 to 10 carbon atoms;
R3 and R4 are independently halogen, hydrogen, alkyl of 1-12 carbon atoms , aryl of 6 to 10 carbon atoms; halogen, trifluoromethylof 1-6 carbon atoms, alkoxyaryl of 7-14 carbon atoms; nitro, amino, carboalkoxy, carbamide, carbamate, urea, alkylsulfoamide, -NR7(CH2)mCO2H, arylsulfoamide, cycloalkyl of 3-8 carbon atoms, or heterocycle of 5 to 7 atom rings containing from 1 to 3 heteroatoms selected from oxygen, nitrogen, or sulfur; R5 is hydrogen, alkyl of 1-6 carbon atoms, -CH(R8)R9, -C(CH2)nCO2R10,
-C(CH3)2CO2R10, -CH(R8)(CH2)nCO2RlO, -CH(R8)C6H4CO2Rl┬░, or _CH2- tetrazole;
R6 is hydrogen, alkyl of 1-6 carbon atoms, halogen, alkyoxy of 1-6 carbon atoms, trifluoroalkyl of 1-6 carbon atoms or trifluoroalkoxy of 1-6 carbon atoms;
R7 is hydrogen or alkyl of 1 to 6 carbon atoms;
R8 is hydrogen, alkyl of 1-6 carbon atoms, aryl of 6-10 carbon atoms, arylalkyl of 7-15 carbon atoms, cycloalkyl of 3-8 carbon atoms, phthalic acid,
R9 is CO2R12, CONHR12, tetrazole, PO3R12;
R10is hydrogen, alkyl of 1-6 carbon atoms, aryl of 6-12 carbon atoms, aralkyl of 7-15 carbon atoms;
R11 is alkylene of 1 to 3 carbon atoms;
R12is hydrogen, alkyl of 1-6 carbon atoms, aryl of 6-12 carbon atoms, aralkyl of 7-15 carbon atoms;
X is O, or S;
Y is O, N, or S;
Z is C, or N;
Q is O, N, or S; m = l-3; n = 1-6; or a pharmaceutically acceptable salt thereof, and a pharmaceutical carrier.
EP99924163A 1998-05-12 1999-05-10 Oxazole-aryl-carboxylic acids useful in the treatment of insulin resistance and hyperglycemia Withdrawn EP1077958A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7671098A 1998-05-12 1998-05-12
US76710 1998-05-12
PCT/US1999/010183 WO1999058511A1 (en) 1998-05-12 1999-05-10 Oxazole-aryl-carboxylic acids useful in the treatment of insulin resistance and hyperglycemia

Publications (1)

Publication Number Publication Date
EP1077958A1 true EP1077958A1 (en) 2001-02-28

Family

ID=22133734

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99924163A Withdrawn EP1077958A1 (en) 1998-05-12 1999-05-10 Oxazole-aryl-carboxylic acids useful in the treatment of insulin resistance and hyperglycemia

Country Status (6)

Country Link
EP (1) EP1077958A1 (en)
JP (1) JP2002514631A (en)
CN (1) CN1308618A (en)
AU (1) AU4073299A (en)
CA (1) CA2331118A1 (en)
WO (1) WO1999058511A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003027095A1 (en) * 2001-09-26 2003-04-03 Bayer Pharmaceuticals Corporation Substituted 3-pyridyl tetrazoles as steroid c17,20 lyase inhibitors
WO2003048140A1 (en) * 2001-12-03 2003-06-12 Japan Tobacco Inc. Azole compound and medicinal use thereof
US7141592B2 (en) * 2003-09-25 2006-11-28 Wyeth Substituted oxadiazolidinediones
AU2005236055B2 (en) 2004-04-20 2011-10-06 Transtech Pharma, Llc Substituted thiazole and pyrimidine derivatives as melanocortin receptor modulators
RU2007106868A (en) 2004-08-23 2008-09-27 Вайет (Us) Oxazole-naphthyl acids and their use as modulators of an inhibitor of plasminogen-1 (PAI) activator for the treatment of thrombosis and cardiovascular diseases
JP2012501334A (en) 2008-08-29 2012-01-19 トランス テック ファーマ，インコーポレイテッド Substituted aminothiazole derivatives, pharmaceutical compositions, and methods of use
CN106749169B (en) * 2016-11-07 2020-04-21 浙江工业大学 Chiral preparation method of Ertiprotafib

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58183676A (en) * 1982-04-19 1983-10-26 Takeda Chem Ind Ltd Oxazole derivative
CA2009470A1 (en) * 1989-02-08 1990-08-08 Yu Momose Oxazole compounds and their use
US5591862A (en) * 1993-06-11 1997-01-07 Takeda Chemical Industries, Ltd. Tetrazole derivatives, their production and use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9958511A1 *

Also Published As

Publication number Publication date
AU4073299A (en) 1999-11-29
CN1308618A (en) 2001-08-15
CA2331118A1 (en) 1999-11-18
JP2002514631A (en) 2002-05-21
WO1999058511A1 (en) 1999-11-18

Similar Documents

Publication Publication Date Title
US6166069A (en) Phenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia
US6110963A (en) Aryl-oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia
WO1999058519A1 (en) Phenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia
US6232322B1 (en) Biphenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia
EP1077967B1 (en) Biphenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia
AU756337B2 (en) Benzothiophenes, benzofurans, and indoles useful in the treatment of insulin resistance and hyperglycemia
US6699896B1 (en) Oxazole-aryl-carboxylic acids useful in the treatment of insulin resistance and hyperglycemia
JP2002514638A (en) 11-aryl-benzo [B] naphtho [2,3-D] furans and 11-aryl-benzo [B] naphtho [2,3-D] thiophenes useful for the treatment of insulin resistance and hyperglycemia
US6221902B1 (en) Biphenyl sulfonyl aryl carboxylic acids useful in the treatment of insulin resistance and hyperglycemia
US6057316A (en) 4-aryl-1-oxa-9-thia-cyclopenta[b]fluorenes
EP1077958A1 (en) Oxazole-aryl-carboxylic acids useful in the treatment of insulin resistance and hyperglycemia
US6001867A (en) 1-aryl-dibenzothiophenes
EP1077966B1 (en) Biphenyl sulfonyl aryl carboxylic acids useful in the treatment of insulin resistance and hyperglycemia
US6310081B1 (en) Biphenyl sulfonyl aryl carboxylic acids useful in the treatment of insulin resistance and hyperglycemia
MXPA00011090A (en) Oxazole-aryl-carboxylic acids useful in the treatment of insulin resistance and hyperglycemia
US6340676B2 (en) 4-aryl-1-oxa-9-thia-cyclopenta (b) fluorenes
MXPA00011083A (en) Phenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia
MXPA00011085A (en) Biphenyl sulfonyl aryl carboxylic acids useful in the treatment of insulin resistance and hyperglycemia
MXPA00011086A (en) Biphenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia
CZ20004182A3 (en) Derivatives of benzothiophene, benzofuran and indole

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20001019

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU NL PT SE

AX Request for extension of the european patent

Free format text: AL PAYMENT 20001019;LT PAYMENT 20001019;LV PAYMENT 20001019;RO PAYMENT 20001019;SI PAYMENT 20001019

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: WYETH

17Q First examination report despatched

Effective date: 20030327

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20030807